Literature DB >> 21597005

An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia.

Christopher T Johansen1, Jian Wang, Matthew B Lanktree, Adam D McIntyre, Matthew R Ban, Rebecca A Martins, Brooke A Kennedy, Reina G Hassell, Maartje E Visser, Stephen M Schwartz, Benjamin F Voight, Roberto Elosua, Veikko Salomaa, Christopher J O'Donnell, Geesje M Dallinga-Thie, Sonia S Anand, Salim Yusuf, Murray W Huff, Sekar Kathiresan, Henian Cao, Robert A Hegele.   

Abstract

OBJECTIVE: Earlier studies have suggested that a common genetic architecture underlies the clinically heterogeneous polygenic Fredrickson hyperlipoproteinemia (HLP) phenotypes defined by hypertriglyceridemia (HTG). Here, we comprehensively analyzed 504 HLP-HTG patients and 1213 normotriglyceridemic controls and confirmed that a spectrum of common and rare lipid-associated variants underlies this heterogeneity. METHODS AND
RESULTS: First, we demonstrated that genetic determinants of plasma lipids and lipoproteins, including common variants associated with plasma triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) from the Global Lipids Genetics Consortium were associated with multiple HLP-HTG phenotypes. Second, we demonstrated that weighted risk scores composed of common TG-associated variants were distinctly increased across all HLP-HTG phenotypes compared with controls; weighted HDL-C and LDL-C risk scores were also increased, although to a less pronounced degree with some HLP-HTG phenotypes. Interestingly, decomposition of HDL-C and LDL-C risk scores revealed that pleiotropic variants (those jointly associated with TG) accounted for the greatest difference in HDL-C and LDL-C risk scores. The APOE E2/E2 genotype was significantly overrepresented in HLP type 3 versus other phenotypes. Finally, rare variants in 4 genes accumulated equally across HLP-HTG phenotypes.
CONCLUSIONS: HTG susceptibility and phenotypic heterogeneity are both influenced by accumulation of common and rare TG-associated variants.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21597005      PMCID: PMC3562702          DOI: 10.1161/ATVBAHA.111.226365

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  28 in total

1.  Idiopathic hyperlipemia: metabolic studies in an affected family.

Authors:  R J HAVEL; R S GORDON
Journal:  J Clin Invest       Date:  1960-12       Impact factor: 14.808

2.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

Review 3.  Genetic determinants of plasma triglycerides.

Authors:  Christopher T Johansen; Sekar Kathiresan; Robert A Hegele
Journal:  J Lipid Res       Date:  2010-11-01       Impact factor: 5.922

4.  Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia.

Authors:  Claudio Priore Oliva; Livia Pisciotta; Giovanni Li Volti; Maria Paola Sambataro; Alfredo Cantafora; Antonella Bellocchio; Alberico Catapano; Patrizia Tarugi; Stefano Bertolini; Sebastiano Calandra
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-12-09       Impact factor: 8.311

5.  Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)

Authors:  S S Anand; S Yusuf; V Vuksan; S Devanesen; K K Teo; P A Montague; L Kelemen; C Yi; E Lonn; H Gerstein; R A Hegele; M McQueen
Journal:  Lancet       Date:  2000-07-22       Impact factor: 79.321

6.  Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease.

Authors:  P W Connelly; G F Maguire; J A Little
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

7.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04

Review 8.  Hypertriglyceridemia: its etiology, effects and treatment.

Authors:  George Yuan; Khalid Z Al-Shali; Robert A Hegele
Journal:  CMAJ       Date:  2007-04-10       Impact factor: 8.262

9.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.

Authors:  Børge G Nordestgaard; Marianne Benn; Peter Schnohr; Anne Tybjaerg-Hansen
Journal:  JAMA       Date:  2007-07-18       Impact factor: 56.272

10.  Missense mutation (Gly----Glu188) of human lipoprotein lipase imparting functional deficiency.

Authors:  M Emi; D E Wilson; P H Iverius; L Wu; A Hata; R Hegele; R R Williams; J M Lalouel
Journal:  J Biol Chem       Date:  1990-04-05       Impact factor: 5.157

View more
  29 in total

1.  The Gene Score for Predicting Hypertriglyceridemia: New Insights from a Czech Case-Control Study.

Authors:  Jaroslav A Hubacek; Dana Dlouha; Vera Adamkova; Lucie Schwarzova; Vera Lanska; Richard Ceska; Martin Satny; Michal Vrablik
Journal:  Mol Diagn Ther       Date:  2019-08       Impact factor: 4.074

2.  Impact of genetic variants in human scavenger receptor class B type I (SCARB1) on plasma lipid traits.

Authors:  Vipavee Niemsiri; Xingbin Wang; Dilek Pirim; Zaheda H Radwan; John E Hokanson; Richard F Hamman; M Michael Barmada; F Yesim Demirci; M Ilyas Kamboh
Journal:  Circ Cardiovasc Genet       Date:  2014-09-22

3.  Association between the GPAM rs1129555 SNP and serum lipid profiles in the Maonan and Han populations.

Authors:  Shuo Yang; Rui-Xing Yin; Liu Miao; Qing-Hui Zhang; Yong-Gang Zhou; Jie Wu
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

4.  Partial LPL deletions: rare copy-number variants contributing towards severe hypertriglyceridemia.

Authors:  Jacqueline S Dron; Jian Wang; Adam D McIntyre; Henian Cao; John F Robinson; P Barton Duell; Priya Manjoo; James Feng; Irina Movsesyan; Mary J Malloy; Clive R Pullinger; John P Kane; Robert A Hegele
Journal:  J Lipid Res       Date:  2019-09-13       Impact factor: 5.922

Review 5.  Chylomicronaemia--current diagnosis and future therapies.

Authors:  Amanda J Brahm; Robert A Hegele
Journal:  Nat Rev Endocrinol       Date:  2015-03-03       Impact factor: 43.330

Review 6.  How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention.

Authors:  Lane B Benes; Daniel J Brandt; Eric J Brandt; Michael H Davidson
Journal:  Curr Cardiol Rep       Date:  2018-10-17       Impact factor: 2.931

7.  Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia.

Authors:  R P Surendran; M E Visser; S Heemelaar; J Wang; J Peter; J C Defesche; J A Kuivenhoven; M Hosseini; M Péterfy; J J P Kastelein; C T Johansen; R A Hegele; E S G Stroes; G M Dallinga-Thie
Journal:  J Intern Med       Date:  2012-02-13       Impact factor: 8.989

Review 8.  Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism.

Authors:  Anne Raimondo; Matthew G Rees; Anna L Gloyn
Journal:  Curr Opin Lipidol       Date:  2015-04       Impact factor: 4.776

Review 9.  The complex genetic basis of plasma triglycerides.

Authors:  Christopher T Johansen; Robert A Hegele
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

Review 10.  Triglyceride Treatment in the Age of Cholesterol Reduction.

Authors:  Nidhi Agrawal; Patricia Freitas Corradi; Namrata Gumaste; Ira J Goldberg
Journal:  Prog Cardiovasc Dis       Date:  2016-08-17       Impact factor: 8.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.